Shire is a holding company. The Company and its subsidiaries is a biopharmaceutical company that focuses on developing and marketing medicines that address unmet patient needs. The Company has four commercial units that focus on the commercial execution of its In-Line products in the following specialist therapeutic areas: rare diseases, neuroscience, gastrointestinal and internal medicine. The Company's main marketed products include VYVANSE/VENVANSE/ELVANSE/TYVENSE (lisdexamfetamine dimesylate) for the treatment of Attention Deficit Hyperactivity Disorder; LIALDA (mesalamine)/ MEZAVANT(mesalazine) for the treatment of ulcerative colitis; as well as REPLAGAL which is marketed for the treatment of Fabry disease.Data provided by Mergent, Inc.
|DR Exchange||NASDAQ Stock Market|
|Effective Date||May 12, 2011|
|Industry||Pharma. & Biotech.|